Clinical trials
Hormones clinical trials
Below are recruiting hormones clinical trials, each written for real people, not researchers. We’re tracking 423 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06490146Recruiting
Menopause, hormones and blood vessel health
This study looks at how the change in hormones during menopause affects blood vessel and nerve health. It involves two visits to test how your body responds to certain changes, helping researchers understand women's heart health during this life stage.
Minneapolis, MinnesotaAges 45–55 - NCT05578053Recruiting
Dalpiciclib for hormone receptor–positive advanced breast cancer
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Shijiazhuang, HebeiAges 18 years+ - NCT06446401Recruiting
Triple vs double therapy for widespread prostate cancer
This trial compares two treatment approaches for men whose prostate cancer has spread widely and is still responding to hormone therapy. It tests whether using three drugs together (triple therapy) works better than two drugs (double therapy) to control the cancer longer.
Uppsala, Region UppsalaAges 18 years+ - NCT06455969RecruitingPhase 4
Stress and recovery training study
This study looks at how the body handles stress, using different hormone levels to create specific conditions in healthy young adults. It aims to understand the body's response and recovery, which may help people build resilience to stress.
Pittsburgh, PennsylvaniaAges 18–40 - NCT06414096RecruitingPhase 1
Pulsatile FSH study for women with obesity or low ovarian reserve
This study tests a new way to give a fertility hormone (FSH) in pulses through a small tube to see if it helps women with obesity or low egg reserve have better egg development with fewer health risks. It may improve fertility treatment outcomes for these women.
Aurora, ColoradoAges 19–37 - NCT06382155RecruitingPhase 2
Vosoritide for children with idiopathic short stature
This trial tests a medication called vosoritide to see if it can help children with unexplained short stature grow taller. It's for kids who are very short for their age but have normal growth hormone levels and no other known cause.
California City, CaliforniaAges 3–11 - NCT06383026Recruiting
Hormone Therapy Breast Cancer Screening Pilot
This pilot study tests a new way to screen for breast cancer in people who have taken hormone therapy (like estrogen, progesterone, or testosterone). It aims to include both men and women between 40 and 75, and younger people (30-39) with a family history of breast cancer.
Milwaukee, WisconsinAges 30–75 - NCT06391034RecruitingPhase 2
MRI scan with pyruvate for prostate cancer
This trial uses a special MRI scan (with hyperpolarized pyruvate, a naturally occurring substance) to look at prostate cancer in more detail. It aims to help doctors understand how the cancer is responding to treatment or how it might behave.
San Francisco, CaliforniaAges 18 years+ - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+ - NCT06023602Recruiting
Generic vs. brand-name cetrorelix for IVF ovarian stimulation
This trial compares a generic version of cetrorelix acetate (a medication used to control ovulation) to the brand-name version during IVF. It aims to see if the generic works just as well for women undergoing ovarian stimulation.
Xi'an, None SelectedAges 20–42 - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT06361940RecruitingPhase 2
Short-term hormone therapy before breast cancer surgery
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06372119Recruiting
Letrozole vs artificial cycle for embryo transfer preparation
This trial compares two ways to prepare the uterus for a frozen embryo transfer: using the hormone letrozole or a standard artificial cycle. The goal is to see which approach works better for people with irregular periods.
Ho Chi Minh City, Ho Chi Minh CityAges 18–42 - NCT06334120Recruiting
Darolutamide safety study for men with prostate cancer in Korea
This study tracks the safety of the drug darolutamide in Korean men with a type of prostate cancer that has not spread (non-metastatic) or has spread (metastatic) and is still responding to hormone therapy. It aims to see how well patients tolerate the drug in real-world settings.
Multiple LocationsAges 19 years+ - NCT06327984Recruiting
Sex hormones and inflammation in heart disease
This study looks at how sex hormones and inflammation affect chest pain and heart disease. It aims to improve care for people with coronary artery disease.
LondonAges 16 years+ - NCT06320067RecruitingPhase 3
Testing treatments for metastatic hormone-sensitive prostate cancer
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
BarnsleyAges 18 years+ - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT06263543RecruitingPhase 2
Sequencing antibody-drug conjugates in ER+, HER2-low breast cancer
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
Miami, FloridaAges 18 years+ - NCT06244004RecruitingPhase 2
PET-guided radiation for metastatic hormone-sensitive prostate cancer
This trial tests whether using a special PET scan (FDG-PET) to find and treat only the spots where cancer has spread with targeted radiation can help men with prostate cancer that has spread but still responds to hormone therapy. It compares standard treatment alone to standard treatment plus this targeted radiation.
Chicago, IllinoisAges 18 years+ - NCT06208904Enrolling by invitation
Gut hormone’s role in post-meal blood pressure drops
This study tests whether a gut hormone called GIP is involved in causing blood pressure drops after eating. It may help find better treatments for people who feel dizzy or faint after meals.
Copenhagen, HellerupAges 18–85 - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06163482Recruiting
Meal Hormone Study in Cystic Fibrosis
This study looks at how the body processes a mixed meal in people with cystic fibrosis who are on CFTR modulator therapy. It may help researchers understand how these medications change hormone and blood sugar responses.
Cincinnati, OhioAges 18–45 - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Tucson, ArizonaAges 18 years+ - NCT06123988Recruiting
Fasting and exercise for advanced breast cancer
This study looks at whether fasting overnight and/or doing exercise can help improve fatigue and other quality-of-life measures in women with advanced hormone receptor positive breast cancer who are already taking a CDK4/6 inhibitor. Participation may involve following a fasting or exercise plan for a period of time.
Phoenix, ArizonaAges 18 years+
Hear when a new Hormones trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormones?
- Yes. Clin2 currently lists 423 recruiting hormones studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormones trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormones trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.